• Product NameRecombinant Murine Interleukin-7
• Host SpeciesEscherichia coli.
• Purification> 96 % by SDS-PAGE and HPLC analyses.
• Biological ActivityFully biologically active when compared to standard. The ED50 as determined by a cell proliferation assay using murine 2E8 cells is less than 0.2 ng/ml, corresponding to a specific activity of > 5.0 x10⁶ IU/mg.
• EndotoxinLess than 1 EU/ug of rMuIL-7 as determined by LAL method.
• Alternative Names    LP-1, pre-B cell factor
• UniprotQ544C8
• Gene ID16196
• Calculated MW Approximately 14.9 kDa, a single non-glycosylated polypeptide chain containing 129 amino acids.
• Target Sequence ECHIKDKEGK AYESVLMISI DELDKMTGTD SNCPNNEPNF FRKHVCDDTK EAAFLNRAAR KLKQFLKMNI SEEFNVHLLT VSQGTQTLVN CTSKEEKNVK EQKKNDACFL KRLLREIKTC WNKILKGSI
• Formulation Lyophilized from a 0.2 μm filtered concentrated solution in PBS, pH 7.4, 2 % trehalose.
• Storage Use a manual defrost freezer and avoid repeated freeze-thaw cycles.- 12 months from date of receipt, -20 to -70 ˚C as supplied.- 1 month, 2 to 8 ˚C under sterile conditions after reconstitution.- 3 months, -20 to -70 ˚C under sterile conditions after reconstitution.

Interleukin-7 (IL-7) is encoded by the IL7 gene in mouse and secreted by stromal cells in the red marrow and thymus. The protein signals through the IL-7 receptor, which is a heterodimer consisting of IL-7 receptor alpha and IL-2 receptor gamma chain. IL-7 stimulates the differentiation of hematopoietic stem cells into lymphoid progenitor cells and it can stimulate proliferation of B cells, T cells and NK cells. Murine IL-7 has approximately 65 % and 88 % amino acid sequence identity with human and rat IL-7 and both proteins exhibit cross-species activity. IL-7 as an immunotherapy agent has been examined in many human clinical trials for various malignancies and during HIV infection.

• Flow Cytometry (FCM) General Protocol
• Immunofluorescence(IC)
• Immunohistochemistry(Polymer)
• Western Blotting